OpenURL Connection Search

Select item for more details and to access through your institution.

Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.
Published in:
Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, n. 8, p. 1365, doi. 10.1002/alz.12302
By:
- Izzo, Nicholas J.;
- Yuede, Carla M.;
- LaBarbera, Kelsie M.;
- Limegrover, Colleen S.;
- Rehak, Courtney;
- Yurko, Raymond;
- Waybright, Lora;
- Look, Gary;
- Rishton, Gilbert;
- Safferstein, Hank;
- Hamby, Mary E.;
- Williams, Claire;
- Sadlek, Kelsey;
- Edwards, Hannah M.;
- Davis, Charles S.;
- Grundman, Michael;
- Schneider, Lon S.;
- DeKosky, Steven T.;
- Chelsky, Daniel;
- Pike, Ian
Publication type:
Article
Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity.
Published in:
PLoS ONE, 2014, v. 9, n. 11, p. 1, doi. 10.1371/journal.pone.0111899
By:
- Izzo, Nicholas J.;
- Xu, Jinbin;
- Zeng, Chenbo;
- Kirk, Molly J.;
- Mozzoni, Kelsie;
- Silky, Colleen;
- Rehak, Courtney;
- Yurko, Raymond;
- Look, Gary;
- Rishton, Gilbert;
- Safferstein, Hank;
- Cruchaga, Carlos;
- Goate, Alison;
- Cahill, Michael A.;
- Arancio, Ottavio;
- Mach, Robert H.;
- Craven, Rolf;
- Head, Elizabeth;
- IIILeVine, Harry;
- Spires-Jones, Tara L.
Publication type:
Article
Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits.
Published in:
PLoS ONE, 2014, v. 9, n. 11, p. 1, doi. 10.1371/journal.pone.0111898
By:
- Izzo, Nicholas J.;
- Staniszewski, Agnes;
- To, Lillian;
- Fa, Mauro;
- Teich, Andrew F.;
- Saeed, Faisal;
- Wostein, Harrison;
- IIIWalko, Thomas;
- Vaswani, Anisha;
- Wardius, Meghan;
- Syed, Zanobia;
- Ravenscroft, Jessica;
- Mozzoni, Kelsie;
- Silky, Colleen;
- Rehak, Courtney;
- Yurko, Raymond;
- Finn, Patricia;
- Look, Gary;
- Rishton, Gilbert;
- Safferstein, Hank
Publication type:
Article
Sigma‐2 receptor antagonists rescue neuronal dysfunction induced by Parkinson's patient brain‐derived α‐synuclein.
Published in:
Journal of Neuroscience Research, 2021, v. 99, n. 4, p. 1161, doi. 10.1002/jnr.24782
By:
- Limegrover, Colleen S.;
- Yurko, Raymond;
- Izzo, Nicholas J.;
- LaBarbera, Kelsie M.;
- Rehak, Courtney;
- Look, Gary;
- Rishton, Gilbert;
- Safferstein, Hank;
- Catalano, Susan M.
Publication type:
Article
Cardiac Targeting Peptide, a Novel Cardiac Vector: Studies in Bio-Distribution, Imaging Application, and Mechanism of Transduction.
Published in:
Biomolecules (2218-273X), 2018, v. 8, n. 4, p. 147, doi. 10.3390/biom8040147
By:
- Zahid, Maliha;
- Feldman, Kyle S.;
- Garcia-Borrero, Gabriel;
- Feinstein, Timothy N.;
- Pogodzinski, Nicholas;
- Xu, Xinxiu;
- Yurko, Raymond;
- Czachowski, Michael;
- Wu, Yijen L.;
- Mason, Neale S.;
- Lo, Cecilia W.
Publication type:
Article
Alzheimer's protection effect of A673T mutation may be driven by lower Aβ oligomer binding affinity.
Published in:
Journal of Neurochemistry, 2021, v. 157, n. 4, p. 1316, doi. 10.1111/jnc.15212
By:
- Limegrover, Colleen S.;
- LeVine, Harry;
- Izzo, Nicholas J.;
- Yurko, Raymond;
- Mozzoni, Kelsie;
- Rehak, Courtney;
- Sadlek, Kelsey;
- Safferstein, Hank;
- Catalano, Susan M.
Publication type:
Article
A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer's disease using an indwelling CSF catheter.
Published in:
2023
By:
- LaBarbera, Kelsie M.;
- Sheline, Yvette I.;
- Izzo, Nicholas J.;
- Yuede, Carla M.;
- Waybright, Lora;
- Yurko, Raymond;
- Edwards, Hannah M.;
- Gardiner, Woodrow D.;
- Blennow, Kaj;
- Zetterberg, Henrik;
- Börjesson-Hanson, Anne;
- Morgan, Roger;
- Davis, Charles S.;
- Guttendorf, Robert J.;
- Schneider, Lon S.;
- DeKosky, Steven;
- LeVine III, Harry;
- Grundman, Michael;
- Caggiano, Anthony O.;
- Cirrito, John R.
Publication type:
Abstract

Found: 7

Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.

Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity.

Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits.

Sigma‐2 receptor antagonists rescue neuronal dysfunction induced by Parkinson's patient brain‐derived α‐synuclein.

Cardiac Targeting Peptide, a Novel Cardiac Vector: Studies in Bio-Distribution, Imaging Application, and Mechanism of Transduction.

Alzheimer's protection effect of A673T mutation may be driven by lower Aβ oligomer binding affinity.

A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer's disease using an indwelling CSF catheter.